Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
Sign Up to like & getrecommendations! Published in 2021 at "BMC Women's Health"
DOI: 10.1186/s12905-021-01475-2
Abstract: Background Uterine leiomyomas are the most common neoplasm affecting women and frequently cause heavy menstrual bleeding and pain. Gonadotropin-releasing hormone (GnRH) receptor antagonists provide fast symptom relief and show promise as a medical (non-surgical) treatment… read more here.
Keywords: uterine leiomyomas; relugolix; trial; treatment ... See more keywords